Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CellSearch study

This article was originally published in The Gray Sheet

Executive Summary

Counting circulating tumor cells with J&J/Veridex's cancer diagnostic system before treatment can independently predict progression-free survival and overall survival rates in patients with metastatic breast cancer, according to a 177-patient trial led by Massimo Cristofanilli, MD, University of Texas, published in the Aug. 19 NEJM. The CellSearch system was 510(k) cleared in June and likely will be commercially available this fall, according to Veridex...

You may also be interested in...



Metastatic Breast Cancer Therapy Effectiveness Gauged By Immunicon Kits

Veridex is rolling out Immunicon's circulating tumor cell selection and enumeration IVD systems to roughly 20 U.S. comprehensive cancer centers and clinical labs

Becton Dickinson, BioMedomics Collaborate On Rapid Serology COVID-19 Test

BD and BioMedomics have released a new rapid point-of-care test that can detect antibodies in blood to confirm current or past exposure to COVID-19.

Industry Asks If Small Business Loan Relief Applies To Companies With Equity Investors

A medtech industry group is asking the Trump administration to clarify if small medical device companies that have equity investors qualify for small business loans and forgiveness under the coronavirus relief package.

UsernamePublicRestriction

Register

MT020754

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel